Triage of high-risk human papillomavirus-positive women by methylated POU4F3

Par Bahadur Pun, Yu Ping Liao, Po Hsuan Su, Hui Chen Wang, Yu Chih Chen, Yaw Wen Hsu, Rui Lan Huang, Cheng Chang Chang, Hung Cheng Lai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Insufficient specificity of the high-risk human papillomavirus (hrHPV) assay in primary cervical cancer screening results in unnecessary referral. Additional assays to triage hrHPV-positive women are needed to improve molecular cervical cancer screening. DNA methylation is a promising biomarker in cervical cancer. We evaluated the clinical performance of potentially methylated genes as a triage assay for hrHPV-positive women. Results: We conducted a retrospective hospital-based case–control study in Taiwan. Cervical scrapings were collected before colposcopy for hrHPV testing and quantitative methylation-specific PCR (QMSP) of 16 genes. Five genes, POU4F3, HS3ST2, AJAP1, PAX1, and SOX1, were prioritized for the clinical performance to triage hrHPV-positive women. Two hundred cervical scrapings were randomly classified into a training set (n = 111) and testing set (n = 89). All samples were tested for hrHPV using a Hybrid Capture II (HCII) assay. HrHPV-positive women were subjected to DNA methylation analysis by QMSP. In the training set, the receiver operating characteristic (ROC) curves defined the optimal methylation index (M-index) cutoff values for discriminating CIN3+ from CIN1/normal, which then were applied to the testing set. Among the five genes, POU4F3 revealed the highest area under the ROC curve (AUC) (0.86; 95 % CI, 0.78–0.95) in detecting CIN3+. In the testing set, POU4F3 revealed the best clinical performance in triage of hrHPV-positive women with a sensitivity of 74 % and specificity of 89 % for detecting CIN3+. Conclusions: POU4F3 methylation analysis is a potential molecular tool for triage in detecting CIN3+ in hrHPV-positive women. The combined use of broad-spectrum HPV assay and POU4F3 methylation analysis as a new generation of molecular cervical cancer screening warrants further population-based study.

Original languageEnglish
Article number85
JournalClinical Epigenetics
Volume7
Issue number1
DOIs
Publication statusPublished - Aug 21 2015

Fingerprint

Triage
Methylation
Uterine Cervical Neoplasms
Early Detection of Cancer
DNA Methylation
ROC Curve
Genes
Polymerase Chain Reaction
Colposcopy
Taiwan
Referral and Consultation
Biomarkers
Sensitivity and Specificity
Population

Keywords

  • Biomarker
  • Cervical cancer screening
  • Cervical intraepithelial neoplasia (CIN)
  • DNA methylation
  • HrHPV test
  • QMSP

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Developmental Biology
  • Genetics(clinical)

Cite this

Triage of high-risk human papillomavirus-positive women by methylated POU4F3. / Pun, Par Bahadur; Liao, Yu Ping; Su, Po Hsuan; Wang, Hui Chen; Chen, Yu Chih; Hsu, Yaw Wen; Huang, Rui Lan; Chang, Cheng Chang; Lai, Hung Cheng.

In: Clinical Epigenetics, Vol. 7, No. 1, 85, 21.08.2015.

Research output: Contribution to journalArticle

Pun, Par Bahadur ; Liao, Yu Ping ; Su, Po Hsuan ; Wang, Hui Chen ; Chen, Yu Chih ; Hsu, Yaw Wen ; Huang, Rui Lan ; Chang, Cheng Chang ; Lai, Hung Cheng. / Triage of high-risk human papillomavirus-positive women by methylated POU4F3. In: Clinical Epigenetics. 2015 ; Vol. 7, No. 1.
@article{8eb06068e0c3424abdbad632eeb66420,
title = "Triage of high-risk human papillomavirus-positive women by methylated POU4F3",
abstract = "Background: Insufficient specificity of the high-risk human papillomavirus (hrHPV) assay in primary cervical cancer screening results in unnecessary referral. Additional assays to triage hrHPV-positive women are needed to improve molecular cervical cancer screening. DNA methylation is a promising biomarker in cervical cancer. We evaluated the clinical performance of potentially methylated genes as a triage assay for hrHPV-positive women. Results: We conducted a retrospective hospital-based case–control study in Taiwan. Cervical scrapings were collected before colposcopy for hrHPV testing and quantitative methylation-specific PCR (QMSP) of 16 genes. Five genes, POU4F3, HS3ST2, AJAP1, PAX1, and SOX1, were prioritized for the clinical performance to triage hrHPV-positive women. Two hundred cervical scrapings were randomly classified into a training set (n = 111) and testing set (n = 89). All samples were tested for hrHPV using a Hybrid Capture II (HCII) assay. HrHPV-positive women were subjected to DNA methylation analysis by QMSP. In the training set, the receiver operating characteristic (ROC) curves defined the optimal methylation index (M-index) cutoff values for discriminating CIN3+ from CIN1/normal, which then were applied to the testing set. Among the five genes, POU4F3 revealed the highest area under the ROC curve (AUC) (0.86; 95 {\%} CI, 0.78–0.95) in detecting CIN3+. In the testing set, POU4F3 revealed the best clinical performance in triage of hrHPV-positive women with a sensitivity of 74 {\%} and specificity of 89 {\%} for detecting CIN3+. Conclusions: POU4F3 methylation analysis is a potential molecular tool for triage in detecting CIN3+ in hrHPV-positive women. The combined use of broad-spectrum HPV assay and POU4F3 methylation analysis as a new generation of molecular cervical cancer screening warrants further population-based study.",
keywords = "Biomarker, Cervical cancer screening, Cervical intraepithelial neoplasia (CIN), DNA methylation, HrHPV test, QMSP",
author = "Pun, {Par Bahadur} and Liao, {Yu Ping} and Su, {Po Hsuan} and Wang, {Hui Chen} and Chen, {Yu Chih} and Hsu, {Yaw Wen} and Huang, {Rui Lan} and Chang, {Cheng Chang} and Lai, {Hung Cheng}",
year = "2015",
month = "8",
day = "21",
doi = "10.1186/s13148-015-0122-0",
language = "English",
volume = "7",
journal = "Clinical Epigenetics",
issn = "1868-7075",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Triage of high-risk human papillomavirus-positive women by methylated POU4F3

AU - Pun, Par Bahadur

AU - Liao, Yu Ping

AU - Su, Po Hsuan

AU - Wang, Hui Chen

AU - Chen, Yu Chih

AU - Hsu, Yaw Wen

AU - Huang, Rui Lan

AU - Chang, Cheng Chang

AU - Lai, Hung Cheng

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Background: Insufficient specificity of the high-risk human papillomavirus (hrHPV) assay in primary cervical cancer screening results in unnecessary referral. Additional assays to triage hrHPV-positive women are needed to improve molecular cervical cancer screening. DNA methylation is a promising biomarker in cervical cancer. We evaluated the clinical performance of potentially methylated genes as a triage assay for hrHPV-positive women. Results: We conducted a retrospective hospital-based case–control study in Taiwan. Cervical scrapings were collected before colposcopy for hrHPV testing and quantitative methylation-specific PCR (QMSP) of 16 genes. Five genes, POU4F3, HS3ST2, AJAP1, PAX1, and SOX1, were prioritized for the clinical performance to triage hrHPV-positive women. Two hundred cervical scrapings were randomly classified into a training set (n = 111) and testing set (n = 89). All samples were tested for hrHPV using a Hybrid Capture II (HCII) assay. HrHPV-positive women were subjected to DNA methylation analysis by QMSP. In the training set, the receiver operating characteristic (ROC) curves defined the optimal methylation index (M-index) cutoff values for discriminating CIN3+ from CIN1/normal, which then were applied to the testing set. Among the five genes, POU4F3 revealed the highest area under the ROC curve (AUC) (0.86; 95 % CI, 0.78–0.95) in detecting CIN3+. In the testing set, POU4F3 revealed the best clinical performance in triage of hrHPV-positive women with a sensitivity of 74 % and specificity of 89 % for detecting CIN3+. Conclusions: POU4F3 methylation analysis is a potential molecular tool for triage in detecting CIN3+ in hrHPV-positive women. The combined use of broad-spectrum HPV assay and POU4F3 methylation analysis as a new generation of molecular cervical cancer screening warrants further population-based study.

AB - Background: Insufficient specificity of the high-risk human papillomavirus (hrHPV) assay in primary cervical cancer screening results in unnecessary referral. Additional assays to triage hrHPV-positive women are needed to improve molecular cervical cancer screening. DNA methylation is a promising biomarker in cervical cancer. We evaluated the clinical performance of potentially methylated genes as a triage assay for hrHPV-positive women. Results: We conducted a retrospective hospital-based case–control study in Taiwan. Cervical scrapings were collected before colposcopy for hrHPV testing and quantitative methylation-specific PCR (QMSP) of 16 genes. Five genes, POU4F3, HS3ST2, AJAP1, PAX1, and SOX1, were prioritized for the clinical performance to triage hrHPV-positive women. Two hundred cervical scrapings were randomly classified into a training set (n = 111) and testing set (n = 89). All samples were tested for hrHPV using a Hybrid Capture II (HCII) assay. HrHPV-positive women were subjected to DNA methylation analysis by QMSP. In the training set, the receiver operating characteristic (ROC) curves defined the optimal methylation index (M-index) cutoff values for discriminating CIN3+ from CIN1/normal, which then were applied to the testing set. Among the five genes, POU4F3 revealed the highest area under the ROC curve (AUC) (0.86; 95 % CI, 0.78–0.95) in detecting CIN3+. In the testing set, POU4F3 revealed the best clinical performance in triage of hrHPV-positive women with a sensitivity of 74 % and specificity of 89 % for detecting CIN3+. Conclusions: POU4F3 methylation analysis is a potential molecular tool for triage in detecting CIN3+ in hrHPV-positive women. The combined use of broad-spectrum HPV assay and POU4F3 methylation analysis as a new generation of molecular cervical cancer screening warrants further population-based study.

KW - Biomarker

KW - Cervical cancer screening

KW - Cervical intraepithelial neoplasia (CIN)

KW - DNA methylation

KW - HrHPV test

KW - QMSP

UR - http://www.scopus.com/inward/record.url?scp=84939543678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939543678&partnerID=8YFLogxK

U2 - 10.1186/s13148-015-0122-0

DO - 10.1186/s13148-015-0122-0

M3 - Article

AN - SCOPUS:84939543678

VL - 7

JO - Clinical Epigenetics

JF - Clinical Epigenetics

SN - 1868-7075

IS - 1

M1 - 85

ER -